Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Cash from Financing Activities of $238.7 million for Q1 2026, up 27216.25% year-over-year from N/an in Q1 2025, and down 34.71% quarter-over-quarter from $365.7 million in Q4 2025.
Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Revolution Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $238.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 27216.25% year-over-year to $238.7 million; the TTM figure through Mar 2026 stood at $859.4 million (down 10.43% YoY), while the FY2025 annual figure was $621.5 million, down 35.22% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $238.7 million, down from $365.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $873.8 million in Q4 2024, with the low at -$1.6 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is $64.6 million (2023), against an average of $197.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 106196.72% in 2023, then slumped 102.06% in 2025.
- Revolution Medicines' Cash from Financing Activities stood at $51.4 million in 2022, then soared by 1534.16% to $839.4 million in 2023, then gained by 4.1% to $873.8 million in 2024, then sank by 58.15% to $365.7 million in 2025, then slumped by 34.71% to $238.7 million in 2026.
- Business Quant data shows RVMD's Cash from Financing Activities at $238.7 million in Q1 2026, $365.7 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -181.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.42 Bn |
| Jun 30, 2026 | 2.42 Bn |
| Mar 31, 2026 | 238.74 Mn |
| Mar 31, 2026 | 238.74 Mn |
| Dec 31, 2025 | 365.66 Mn |
| Dec 31, 2025 | 365.66 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | 256.58 Mn |
| Jun 30, 2025 | 256.58 Mn |
| Mar 31, 2025 | 874,000.00 |
| Mar 31, 2025 | 874,000.00 |
| Dec 31, 2024 | 873.81 Mn |
| Dec 31, 2024 | 873.81 Mn |
| Sep 30, 2024 | 77.29 Mn |
| Sep 30, 2024 | 77.29 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 810,000.00 |
| Mar 31, 2024 | 810,000.00 |